MIMarcos Blancarte Ibarra

Marcos Blancarte Ibarra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcos Blancarte Ibarra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.

    by Elysa Cortez, Erick Torres Luna, Marcos Blancarte Ibarra, Imelda E Riojas Suárez, Herney A Garcia-Perdomo, Cristhiam M Rojas Hernandez

    Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.